SCHEMBL4149264

SCHEMBL4149264

FC(F)(F)c1cc(-c2cc3c4ccccc4ccc3n2-c2ccccc2)cc(C(F)(F)F)c1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 1/20 0.37
ATM Q13315 1/20 0.37
L3MBTL1 Q9Y468 1/20 0.37
MAT2A P31153 1/20 0.36
P2RX1 P51575 1/20 0.36
P2RX3 P56373 1/20 0.36
P2RX4 Q99571 1/20 0.36
P2RX7 Q99572 1/20 0.36
GAA P10253 2/20 0.35
MGAM O43451 1/20 0.35
SI P14410 1/20 0.35
MGAM2 Q2M2H8 1/20 0.35
ALDH1A1 P00352 2/20 0.35
TDP1 Q9NUW8 1/20 0.35
LMNA P02545 1/20 0.35
NPSR1 Q6W5P4 1/20 0.35
TDP2 O95551 1/20 0.35
CYP1A1 P04798 1/20 0.34
CYP1A2 P05177 1/20 0.34
CYP1B1 Q16678 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4155464 0.90 MGAM (0.42) KDM4EATML3MBTL1MAT2AGAA
SCHEMBL2991546 0.87 PLA2G10 (0.43) KDM4EL3MBTL1GAAALDH1A1TDP1
SCHEMBL2997524 0.82 CYP1A2 (0.50) CYP1A2PDPK1ICMTPPARGPPARA
SCHEMBL12076916 0.79 L3MBTL1 (0.37) KDM4EATML3MBTL1ALDH1A1TDP1
SCHEMBL2986744 0.79 KMT2A (0.49) KDM4EALDH1A1CNR2PPARGPPARA
SCHEMBL2986715 0.77 PTGER1 (0.44) KDM4EL3MBTL1GAAALDH1A1TDP1
SCHEMBL4140780 0.77 ALDH1A1 (0.43) KDM4EATML3MBTL1MAT2AALDH1A1
SCHEMBL4148824 0.75 EGFR (0.46) KDM4EATML3MBTL1MGAMALDH1A1
SCHEMBL12091770 0.74 PTGER4 (0.45) KDM4EL3MBTL1ALDH1A1NPSR1
SCHEMBL4148027 0.73 DHODH (0.41) KDM4EATML3MBTL1MAT2AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9216966-B2 Compounds for Alzheimer's disease Manfredi, John (US) 2015-12-22 US disclosed
US-20130261118-A1 COMPOUNDS FOR ALZHEIMER'S DISEASE MANFREDI JOHN (US) 2013-10-03 US disclosed
US-20090099179-A1 COMPOUNDS FOR DISEASES AND DISORDERS MYRIAD GENETICS, INCORPORATED (US) 2009-04-16 US disclosed
US-20080249135-A1 N-phenylindoles; oral dosage forms; side effect reduction MYRIAD GENETICS, INCORPORATED (US) 2008-10-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130261118-A1 COMPOUNDS FOR ALZHEIMER'S DISEASE SLC18A2, SLC18A3, NLN KDM4E 3751/4885ATM 2030/4885L3MBTL1 2424/4885
US-20090099179-A1 COMPOUNDS FOR DISEASES AND DISORDERS CLN6, NLN, CLTC KDM4E 4625/4885ATM 4581/4885L3MBTL1 191/4885
US-20080249135-A1 N-phenylindoles; oral dosage forms; side effect reduction NCL, PSEN2, CCNO KDM4E 2603/4885ATM 4208/4885L3MBTL1 170/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.